1. |
Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-seventh Official Adult Lung and Heart–Lung Transplant Report—2010. J Heart Lung Transplant, 2010, 29(10): 1104-1118.
|
2. |
Yusen RD, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtythird Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant, 2016, 35(10): 1170-1184.
|
3. |
Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report-2011. J Heart Lung Transplant, 2011, 30(10): 1104-1122.
|
4. |
黄洁夫. 中国器官移植发展报告. 北京: 中国科学技术出版社, 2020, 46-52.
|
5. |
King CS, Khandhar S, Burton N, et al. Native lung complications in single-lung transplant recipients and the role of pneumonectomy. J Heart Lung Transplant, 2009, 28: 851-856.
|
6. |
Fischer SA, Avery RK; the AST Infectious Disease Community of Practice. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant, 2009, 9(Suppl 4): S7-S18.
|
7. |
Bonde PN, Patel ND, Borja MC, et al. Impact of donor lung organisms on post-lung transplant pneumonia. J Heart Lung Transplant, 2006, 25: 99-105.
|
8. |
Verleden GM, Vos R, van Raemdonck D, et al. Pulmonary infection defense after lung transplantation: does airway ischemia play a role?. Curr Opin Organ Transplant, 2010, 15: 568-571.
|
9. |
Murthy SC, Gildea TR, Machuzak MS. Anastomotic airway complications after lung transplantation. Curr Opin Organ Transplant, 2010, 15: 582-587.
|
10. |
Parada MT, Alba A, Sepúlveda C. Early and late infections in lung transplantation patients. Transplant Proc, 2010, 42(1): 333-335.
|
11. |
Neofytos D, Treadway S, Ostrander D, et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect Dis, 2013, 15(3): 233-242.
|
12. |
卫栋, 范立, 班乐. 中国肺移植术后并发症诊疗和随访技术规范(2019版). 中华移植杂志(电子版), 2019, 13(2): 99-108.
|
13. |
周燕飞, 邓敏. 连续3年临床分离鲍曼不动杆菌临床分布及耐药性. 中国感染控制杂志, 2015, 14(1): 42-44.
|
14. |
Nęcki M, Gawęda M, Pandel A, et al. Microbiological status as a factor of airway complications after lung transplantation. Transplant Proc, 2020, 52(7): 2149-2154.
|
15. |
张秀红, 缪丽燕, 陈静瑜, 等. 呼吸重症监护病房肺移植术后患者早期感染病原菌分布与耐药性. 中国感染控制杂志, 2020, 19(9): 785-790.
|
16. |
Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis, 2009, 48(12): 1657-1665.
|
17. |
Longworth SA, Daly JS; the AST Infectious Diseases Community of Practice. Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant, 2019, 33(9): e13588.
|
18. |
Chalermskulrat W, Sood N, Neuringer IP, et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax, 2006, 61: 507-513.
|
19. |
Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax, 2008, 63(8): 732-737.
|
20. |
Tavares M, Kozak M, Balola A, et al. Burkholderia cepacia complex bacteria: a feared contamination risk in water-based pharmaceutical products. Clin Microbiol Rev, 2020, 33(3): e00139-19.
|
21. |
Potena L, Solidoro P, Patrucco F, et al. Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update. Expert Opini Pharmacother, 2016, 17(12): 1611-1622.
|
22. |
Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis, 2017, 64(1): 87-91.
|
23. |
Humar A, Snydman D; the AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant, 2009, 9(Suppl 4): S78-S86.
|
24. |
Krishnam MS, Suh RD, Tomasian A, et al. Postoperative complications of lung transplantation: radiologic findings along a time continuum. Radiographics, 2007, 27(4): 957-974.
|
25. |
Snyder LD, Finlen-Copeland CA, Turbyfill WJ, et al. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med, 2010, 181: 1391-1396.
|
26. |
Kotton CN, Kumar D, Caliendo AM, et al. International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. Transplantation, 2010, 89: 779-795.
|
27. |
Courtwright AM, Burkett P, Divo M, et al. Posttransplant lymphoproliferative disorders in Epstein-Barr virus donor positive/recipient negative lung transplant recipients. Ann Thorac Surg, 2018, 105(2): 441-447.
|
28. |
Peghin M, Los-Arcos I, Hirsch HH, et al. Communityacquired respiratory viruses are a risk factor for chronic lung allograft dysfunction. Clin Infect Dis, 2019, 69(7): 1192-1197.
|
29. |
Solé A, Salavert M. Fungal infections after lung transplantation. Curr Opin Pulm Med, 2009, 15(3): 243-253.
|
30. |
Vazquez R, Vazquez-Guillamet MC, Suarez J, et al. Invasive mold infections in lung and heart-lung transplant recipients: Stanford University experience. Transpl Infect Dis, 2015, 17(2): 259-266.
|
31. |
Doligalski CT, Benedict K, Cleveland AA, et al. Epidemiology of invasive mold infections in lung transplant recipients. Am J Transplant, 2014, 14(6): 1328-1333.
|
32. |
Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant, 2009, 9(8): 1903-1911.
|
33. |
Sims KD, Blumberg EA. Common infections in the lung transplant recipient. Clin Chest Med, 2011, 32: 327-341.
|
34. |
Baker AW, Maziarz EK, Arnold CJ, et al. Invasive fungal infection after lung transplantation: epidemiology in the setting of antifungal prophylaxis. Clin Infect Dis, 2019, 70(1): 30-39.
|
35. |
Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clin Infect Dis, 2008, 46: 327-360.
|
36. |
Silveira FP, Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med, 2008, 14: 211-218.
|
37. |
Ramanan P, Scherger S, Benamu E, et al. Toxoplasmosis in non-cardiac solid organ transplant recipients: a case series and review of literature. Transplant Infect Dis, 2020, 22(1): e13218.
|
38. |
Cooper AJR, Dholakia S, Holland CV, et al. Helminths in organ transplantation. Lancet Infect Dis, 2017, 17(6): e166-e176.
|
39. |
Garcia HH, Nash TE, Del Brutto OH. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol, 2014, 13(12): 1202-1215.
|
40. |
Burguete SR, Maselli DJ, Fernandez JF, et al. Lung transplant infection. Respirology, 2013, 18(1): 22-38.
|
41. |
Razonable RR, Humar A. Cytomegalovirus in Solid Organ Transplant Recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant, 2019, 33(9): e13512.
|
42. |
Lee DH, Zuckerman RA. Herpes Simplex Virus Infections in Solid Organ Transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant, 2019, 33(9): e13526.
|
43. |
Nosotti M, Tarsia P, Morlacchi LC. Infections after lung transplantation. J Thorac Dis, 2018, 10(6): 3849-3868.
|
44. |
操梅林, 徐燕丽, 张秀群, 等. 泊沙康唑预防侵袭性真菌感染有效性及安全性的荟萃分析. 中国感染与化疗杂志, 2015, 15(14): 309-314.
|